Inventiva announces trading resumption of its ordinary shares on Euronext Paris

Core Points - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [3] - The trading of Inventiva's ordinary shares on Euronext Paris resumed on November 13, 2025, at 4:30 p.m. CET after a halt for a public offering in the United States [1][2] Company Overview - Inventiva is engaged in the research and development of oral small molecule therapies specifically targeting MASH, a progressive chronic liver disease [3] - The company is currently conducting the NATiV3 pivotal Phase 3 clinical trial for lanifibranor, a novel pan-PPAR agonist aimed at treating adult patients with MASH [3] Trading Information - Trading of the company's ordinary shares was halted at its request on November 13, 2025, at 9:00 a.m. CET to facilitate the public offering of new American Depositary Shares [2] - The offering involved new American Depositary Shares, each representing one new ordinary share with a nominal value of €0.01 [2]